Recent Updates — ANVS

The New York Stock Exchange notified Annovis Bio that it is no longer in compliance with continued listing standards due to a 30-day average market capitalization of approximately $48.4 million and a stockholders' deficit of $(4.3) million as of June 30, 2026. The company must submit a plan within 45 days to regain conformity within nine months or face delisting proceedings. Trading continues under the symbol ANVS with a .BC designation indicating non-compliance. Annovis Bio is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases.

Annovis Bio, Inc. announced on July 7, 2026, that its pivotal Phase 3 trial (NCT06709014) evaluating buntanetap for early Alzheimer's Disease (AD) has reached full enrollment of 850 patients with pTau217-confirmed AD pathology across 83 clinical sites in the United States. Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases.